Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recruiting × sugemalimab × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm, Residual 1

Interventions

Cisplatin 19 pembrolizumab 17 Gemcitabine 13 Paclitaxel 12 Carboplatin 12 Drug Therapy 10 Magnetic Resonance Spectroscopy 8 Dexamethasone 8 venetoclax 7 Docetaxel 7 Bevacizumab 7 atezolizumab 6 Nivolumab 6 Methotrexate 6 Cytarabine 6 Cyclophosphamide 6 durvalumab 5 Specimen Handling 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Capecitabine 5 130-nm albumin-bound paclitaxel 5 Taxes 4 Standard of Care 4 Injections 4 Fluorouracil 4 Daunorubicin 4 Azacitidine 4 spartalizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05623267 2023-08-07

SURPASS

Sun Yat-sen University

Phase 2/3 Recruiting

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡